FDA grants priority review for crush-resistant, long-acting oxymorphone

CHADDS FORD, Pa. The Food and Drug Administration has granted priority review to an opioid painkiller designed to thwart drug abusers.


Endo Pharmaceuticals said Wednesday that the FDA would expedite review of its new oral formulation of long-acting oxymorphone, which is designed to be crush-resistant. The FDA expects to take action on the drug in early January.



The drug is designed to treat moderate to severe chronic pain in patients requiring around-the-clock treatment for a long period of time. It is a tablet designed to resist crushing, breaking, powdering or pulverizing.


Login or Register to post a comment.